Peter Hedlin
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
Papers in
-
- Prion Diseases and Protein Misfolding 3
- Cancer therapeutics and mechanisms 2
- Phenothiazines and Benzothiazines Synthesis and Activities 2
-
- Antibiotics Pharmacokinetics and Efficacy 6
- Co-authors
- Joseph M. Blondeau (8 shared papers)K. Metzler (4 shared papers)Gary L. Hansen (2 shared papers)G. Hansen (2 shared papers)Karl Drlica (1 shared paper)Andrew Potter (3 shared papers)Philip Griebel (3 shared papers)Scott Napper (3 shared papers)
In The Last Decade
Peter Hedlin
15 papers receiving 257 citations
Peers
Comparison fields: 5 of 63
- Molecular Medicine 91
- Applied Microbiology and Biotechnology 22
- Pharmacology 134
- Ophthalmology 53
- Clinical Biochemistry 33
Countries citing papers authored by Peter Hedlin
This map shows the geographic impact of Peter Hedlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hedlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hedlin more than expected).
Fields of papers citing papers by Peter Hedlin
This network shows the impact of papers produced by Peter Hedlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hedlin. The network helps show where Peter Hedlin may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Hedlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 115 | |
| 2 | 2004 | 94 | |
| 3 | 2009 | 27 | |
| 4 | 2014 | 14 | |
| 5 | 2007 | 11 | |
| 6 | 2012 | 10 | |
| 7 | 2024 | 6 | |
| 8 | 2022 | 5 | |
| 9 | The Antimicrobial Activity of Gatifloxcin (GAT) With or Without Benzalkonium Chloride (BAK) Against Ocular Bacterial Pathogens | 2005 | 4 |
| 10 | 2021 | 3 | |
| 11 | Comparative Minimal Inhibitory and Mutant Prevention Concentration (MPC) Of Gatifloxacin (GA) and Other Compounds Against Gram–Positive Ocular Pathogens | 2004 | 2 |
| 12 | Determination of Minimal Inhibitory Concentration (MIC) and Mutant Prevention Concentration (MPC) of Ocular Isolates of Pseudomonas aeruginosa (PA) and Haemophilus influenzae (HI) to 5 Fluorquinolone (FQ) Antimicrobial Agents (AA). | 2004 | 2 |
| 13 | 2024 | 1 | |
| 14 | The Killing of Ocular Isolates of Pseudomonas aeruginosa (PA) and Klebsiella pneumoniae (KP) by Gatifloxacin (GA) – A New Fluoroquinolone (FQ). | 2004 | 1 |
| 15 | 2003 | 1 |
About Peter Hedlin
Peter Hedlin is a scholar working on Molecular Biology, Pharmacology, Molecular Medicine, Ophthalmology and Infectious Diseases, having authored 15 papers that have together received 296 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (6 papers), Antibiotic Resistance in Bacteria (6 papers), Ocular Infections and Treatments (3 papers), Prion Diseases and Protein Misfolding (3 papers), Cancer therapeutics and mechanisms (2 papers), Phenothiazines and Benzothiazines Synthesis and Activities (2 papers), Food Allergy and Anaphylaxis Research (2 papers) and Long-Term Effects of COVID-19 (1 paper). The work is most often cited by research in Molecular Medicine (91 citations), Applied Microbiology and Biotechnology (22 citations), Pharmacology (134 citations), Ophthalmology (53 citations) and Clinical Biochemistry (33 citations). Peter Hedlin has collaborated with scholars based in Canada and India. Frequent co-authors include Joseph M. Blondeau, K. Metzler, Gary L. Hansen, G. Hansen, Karl Drlica, Andrew Potter, Philip Griebel, Scott Napper, Neil R. Cashman and Li Li. Their work appears in journals such as Investigative Ophthalmology & Visual Science, Canadian Journal of Anesthesia/Journal canadien d anesthésie, Journal of Chemotherapy, Scientific Reports and BMJ Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.